TRP Channel Antagonist

TRP Channel Antagonists (69):

Cat. No.	Product Name	Effect	Purity

HY-15640

Capsazepine	Antagonist	99.17%
Capsazepine is a synthetic analogue of the sensory neurone excitotoxin, and an antagonist of TRPV1 receptor with an IC₅₀ of 562 nM.

HY-100208

HC-067047	Antagonist	99.78%
HC-067047 is a potent and selective TRPV4 antagonist and reversibly inhibits currents through the human, rat, and mouse TRPV4 orthologs with IC₅₀ values of 48 nM, 133 nM, and 17 nM, respectively.

HY-100720

GSK2193874	Antagonist	99.74%
GSK2193874 is an orally active, potent, and selective TRPV4 antagonist with IC₅₀s of 2 nM and 40 nM for rTRPV4 and hTRPV4.

HY-101736

AMG9810	Antagonist	99.83%
AMG9810 is a selective and competitive vanilloid receptor 1 (TRPV1) antagonist with IC₅₀ values of 24.5 and 85.6 nM for human and rat TRPV1, repectively.

HY-120691A

GSK205	Antagonist	99.91%
GSK205 is a potent, selective TRPV4 antagonist with an IC₅₀ of 4.19 μM for inhibiting TRPV4-mediated Ca²⁺ influx.

HY-111925

BI-749327	Antagonist	99.50%
BI-749327 is a potent, high selectivity and orally bioavailable TRPC6 antagonist, with IC₅₀s of 13 nM, 19 nM and 15 nM for mouse, human and guinea pig TRPC6, respectively. BI-749327 is 85-fold more selective for mouse TRPC6 than TRPC3 and 42-fold versus TRPC7.

HY-108463

A-967079	Antagonist	99.30%
A-967079 is a selective TRPA1 receptor antagonist with IC₅₀s of 67 nM and 289 nM at human and rat TRPA1 receptors, respectively, and has good penetration into the CNS.

HY-12245

SB-366791	Antagonist	98.11%
SB-366791 is a potent and selective vanilloid receptor (VR1/TRPV1) antagonist (IC₅₀=5.7 nM). SB-366791 can be used for the research of inflammation.

HY-10633

SB-705498	Antagonist	99.98%
SB-705498 is a potent, selective and orally bioavailable transient receptor potential vanilloid 1 (TRPV1) receptor antagonist with a pIC₅₀ of 7.1.

HY-112430

TRPM8 antagonist 2	Antagonist	98.01%
TRPM8 antagonist 2 is a potent and selective TRPM8 antagonist, with an IC₅₀ of 0.2 nM, used in the research of neuropathic pain syndromes.

HY-10634

AMG 517	Antagonist	99.97%
AMG 517 is a potent and selective vanilloid receptor-1 (TRPV1) antagonist with an IC₅₀ of 0.5 nM.

HY-112302

HC-070	Antagonist	99.73%
HC-070 is an antagonist of TRPC4/TRPC5, with IC₅₀s of 9.3 nM and 46 nM for hTRPC5 and hTRPC4 in cells, respectively.

HY-19975

RN-1734	Antagonist	99.86%
RN-1734 is selective antagonist of the TRPV4 channel, completely antagonizes 4αPDD-mediated activation of TRPV4 with comparable, low micromolar IC₅₀s for all three species (hTRPV4: 2.3 μM, mTRPV4: 5.9 μM, rTRPV4: 3.2 μM). RN-1734 clearly decreases the production of tumor necrosis factor α (TNF-α) and interleukin 1β (IL-1β) without altering the number of olig2-positive cells.

HY-19960

BCTC	Antagonist	98.03%
BCTC is an orally active current inhibitor of vanilloid receptor type 1 (VR1). BCTC is a transient receptor potential cation channel subfamily M member 8 (TRPM8) and transient receptor potential vanilloid 1 (TRPV1) antagonist. BCTC is an insulin sensitizer and secretor. BCTC has anticancer and analgesic effects.

HY-18662

RQ-00203078	Antagonist	99.84%
RQ-00203078 is a highly selective, potent and orally active TRPM8 antagonist with IC₅₀s of 5.3 nM and 8.3 nM for rat and human TRPM8 channels, respectively. RQ-00203078 shows little inhibitory action against TRPV1, TRPA1, TRPV4, or TRPM2 channels.

HY-132222

SET2	Antagonist	99.72%
SET2 is a selective TRPV2 antagonist (IC₅₀=0.46 μM). SET2 blocks the TRP channel and suppresses prostate cancer cells migration. SET2 reduces the lysophosphatidic acid (LPA, a TRPV2 activator)-induced cytoplasmic calcium increases.

HY-12777

Asivatrep	Antagonist
Asivatrep (PAC-14028) is a potent and selective transient receptor potential vanilloid type I (TRPV1) antagonist.

HY-N1378

(E)-Cardamonin	Antagonist	99.77%
(E)-Cardamonin ((E)-Cardamomin) is a novel antagonist of hTRPA1 cation channel with an IC₅₀ of 454 nM.

HY-108329

AM-0902	Antagonist	99.65%
AM-0902 is a potent, selective transient receptor potential A1 (TRPA1) antagonist with IC₅₀s of 71 and 131 nM for rTRPA1 and hTRPA1, respectively.

HY-P1651A

SOR-C13 TFA	Antagonist	99.18%
SOR-C13 TFA, a carboxy-terminal truncated peptide, is a high-affinity TRPV6 antagonist with an IC₅₀ value of 14 nM. TRPV6 is a non-voltage gated calcium channel that is associated with malignancy and poor prognosis in breast cancer. SOR-C13 TFA has anticancer activity.

Name
Email *

	Sorry, but the email address you supplied was invalid.